MA31254B1 - Anticorps contre erbb3 et leur utilisation - Google Patents

Anticorps contre erbb3 et leur utilisation

Info

Publication number
MA31254B1
MA31254B1 MA32222A MA32222A MA31254B1 MA 31254 B1 MA31254 B1 MA 31254B1 MA 32222 A MA32222 A MA 32222A MA 32222 A MA32222 A MA 32222A MA 31254 B1 MA31254 B1 MA 31254B1
Authority
MA
Morocco
Prior art keywords
erbb3
antibodies
receptor
egf
bind
Prior art date
Application number
MA32222A
Other languages
Arabic (ar)
English (en)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MA31254B1 publication Critical patent/MA31254B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE NOUVELLE CLASSE D'ANTICORPS MONOCLONAUX QUI SE LIENT AU RÉCEPTEUR ERBB3 ET INHIBE DIVERSES FONCTIONS DE ERBB3. PAR EXEMPLE, LES ANTICORPS DÉCRITS ICI SONT CAPABLES DE SE LIER À ERBB3 ET D'INHIBER LA PHOSPHORYLATION DU RÉCEPTEUR INDUITE PAR UN LIGAND DE TYPE EGF.
MA32222A 2007-02-16 2009-09-15 Anticorps contre erbb3 et leur utilisation MA31254B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90190407P 2007-02-16 2007-02-16
US979608P 2008-01-02 2008-01-02
PCT/US2008/002119 WO2008100624A2 (fr) 2007-02-16 2008-02-15 Anticorps contre erbb3 et leur utilisation

Publications (1)

Publication Number Publication Date
MA31254B1 true MA31254B1 (fr) 2010-03-01

Family

ID=39690706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32222A MA31254B1 (fr) 2007-02-16 2009-09-15 Anticorps contre erbb3 et leur utilisation

Country Status (29)

Country Link
US (8) US7846440B2 (fr)
EP (4) EP2716301B1 (fr)
JP (2) JP5564266B2 (fr)
KR (1) KR101598229B1 (fr)
CN (1) CN101674846B (fr)
AU (1) AU2008216600B2 (fr)
BR (1) BRPI0808055A2 (fr)
CA (1) CA2678181C (fr)
CO (1) CO6231000A2 (fr)
CR (1) CR11029A (fr)
CY (1) CY1114632T1 (fr)
DK (2) DK2129396T3 (fr)
EA (1) EA020465B1 (fr)
EC (1) ECSP099637A (fr)
ES (2) ES2431940T3 (fr)
HK (1) HK1138771A1 (fr)
HR (2) HRP20131113T1 (fr)
HU (1) HUE033472T2 (fr)
IL (1) IL200373A (fr)
MA (1) MA31254B1 (fr)
MX (1) MX2009008656A (fr)
NZ (1) NZ579644A (fr)
PL (2) PL2716301T3 (fr)
PT (2) PT2129396E (fr)
RS (1) RS53042B (fr)
SG (1) SG178789A1 (fr)
SI (2) SI2129396T1 (fr)
WO (1) WO2008100624A2 (fr)
ZA (1) ZA200906360B (fr)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
JP4660094B2 (ja) 2002-03-26 2011-03-30 ゼンサン （シャンハイ） サイ−テク． リミテッド 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
CA2821167C (fr) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Liposomes pour l'administration de drogues contenant des polyols anioniques ou des sucres anioniques
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
ES2433424T3 (es) * 2008-08-15 2013-12-11 Merrimack Pharmaceuticals, Inc. Métodos y sistemas para predecir respuesta de células frente a un agente terapéutico
EP2408817B1 (fr) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Anticorps anti-her di-spécifiques
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
BRPI1010297A2 (pt) * 2009-04-07 2017-06-06 Roche Glycart Ag anticorpos biespecíficos trivalentes.
CN102361883A (zh) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-1/抗-c-Met抗体
SG175081A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
EP2430047B1 (fr) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Molécules neutralisantes dirigées contre les virus de la grippe
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EA201200195A1 (ru) * 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AU2010303443A1 (en) * 2009-10-09 2012-04-19 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-Her 3 antibodies
WO2011047180A1 (fr) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Agents de liaison bispécifiques qui ciblent la signalisation igf-1r et erbb3, et leurs utilisations
JP2013507928A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011056124A1 (fr) * 2009-11-04 2011-05-12 Affibody Ab Polypeptides de liaison de her3
ES2655737T3 (es) 2009-11-13 2018-02-21 Daiichi Sankyo Europe Gmbh Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3
WO2011060380A1 (fr) * 2009-11-14 2011-05-19 The Regents Of The University Of California L'état de mutation de pik3ca et l'expression de sash1 prédisent la synergie entre le lapatinib et un inhibiteur d'akt dans le cancer du sein her2 positif
CA2782571C (fr) 2009-12-22 2018-01-23 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
US20120010388A1 (en) * 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
KR20130060223A (ko) 2010-05-04 2013-06-07 메리맥 파마슈티컬즈, 인크. 상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
NZ603570A (en) * 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
CA2804399A1 (fr) 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anticorps anti-ron
WO2012006552A1 (fr) * 2010-07-09 2012-01-12 Exelixis, Inc. Associations d'inhibiteurs de kinases destinées au traitement du cancer
WO2012018790A2 (fr) 2010-08-03 2012-02-09 Abbott Laboratories Immunoglobulines à double domaine variable et utilisations associées
WO2012019024A2 (fr) * 2010-08-04 2012-02-09 Immunogen, Inc. Molécules se liant à her3 et leurs immunoconjugués
UA114883C2 (uk) 2010-08-20 2017-08-28 Новартіс Аг Антитіло до рецептора епідермального фактора росту-3 (her3)
CA2807278A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Anticorps bispecifiques comprenant un fragment fv stabilise par bisulfure
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2630160B1 (fr) * 2010-10-18 2016-11-09 MediaPharma S.r.l. Anticorps se liant à erbb3
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
DK2635604T3 (en) * 2010-11-01 2017-02-27 Symphogen As PAN-HER-ANTIBODY COMPOSITION
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
EP2648738A2 (fr) 2010-12-06 2013-10-16 Merrimack Pharmaceuticals, Inc. Détermination de la dose et administration pour la prévention de la cardiotoxicité dans le traitement par immunoliposomes ciblant erbb2 comprenant des agents chimiothérapeutiques à base d'anthracycline
SG191230A1 (en) * 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012099968A1 (fr) * 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions et procédés de traitement de maladies associées à un cancer de la peau
AU2012211258A1 (en) * 2011-01-27 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-ErbB3 antibodies
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
WO2012116927A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Protéines monovalentes de liaison à l'antigène
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
EP2683290B1 (fr) 2011-03-07 2018-11-07 F.Hoffmann-La Roche Ag Procédés destinés aux tests in vivo d'anticorps thérapeutiques
CN103562226A (zh) * 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CA2828043A1 (fr) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Vaincre la resistance a des inhibiteurs de la voie erbb
TWI631136B (zh) * 2011-04-19 2018-08-01 莫瑞麥克製藥公司 單特異性及雙特異性抗ｉｇｆ－１ｒ及抗ｅｒｂｂ３抗體
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
KR20140050609A (ko) * 2011-05-06 2014-04-29 메리맥 파마슈티컬즈, 인크. 항-ＥｒｂＢ3 제제들을 포함하는 조합 요법들에서 독성의 약물-약물 상호작용들을 예방하는 방법들
ES2657862T3 (es) 2011-05-13 2018-03-07 Gamamabs Pharma Anticuerpos contra HER3
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
JP2014516960A (ja) * 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
WO2012173867A1 (fr) * 2011-06-16 2012-12-20 Merrimack Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-erbb3 en combinaison avec des inhibiteurs de tyrosine kinase
AU2012274461A1 (en) * 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
WO2012177440A1 (fr) * 2011-06-24 2012-12-27 Merrimack Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-erbb3 en association avec le paclitaxel
CA2839869A1 (fr) * 2011-06-30 2013-01-03 Sanofi Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynecologiques
EP2736928B1 (fr) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Proteines "sur"-liantes dirigees contre erbb3
WO2013023043A2 (fr) * 2011-08-10 2013-02-14 Merrimack Pharmaceuticals, Inc. Traitement de tumeurs solides avancées à l'aide d'une combinaison d'une immunothérapie anti-erbb3 et d'une chimiothérapie sélectionnée
AU2012300279A1 (en) 2011-08-26 2014-04-03 Merrimack Pharmaceuticals, Inc. Tandem Fc bispecific antibodies
KR20140069331A (ko) * 2011-09-30 2014-06-09 리제너론 파아마슈티컬스, 인크. 항-ＥｒｂＢ3 항체 및 이의 용도
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2764364B1 (fr) 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Prédiction de réaction de tumeur à des anticorps anti-erbb3
CN104011079B (zh) * 2011-11-09 2017-06-16 Uab研究基金会 Her3抗体及其用途
EP3608340A1 (fr) 2011-11-23 2020-02-12 Medlmmune, LLC Molécules de liaison propres à her3 et utilisation de celles-ci
UY34487A (es) 2011-12-05 2013-07-31 Novartis Ag Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
KR102092147B1 (ko) 2012-01-13 2020-03-23 닛뽕 케미파 가부시키가이샤 P2x4 수용체 길항제
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
JP2015509492A (ja) * 2012-02-22 2015-03-30 ユー３・ファーマ・ゲーエムベーハー Ｈｂ−ｅｇｆ結合タンパク質およびｅｇｆｒ阻害剤の組合せ
WO2013138371A1 (fr) * 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Procédés de traitement du cancer du pancréas à l'aide de thérapies combinées comprenant un anticorps anti-erbb3
CA2865082A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Diagnostic et traitements concernant des inhibiteurs de her3
KR101933990B1 (ko) 2012-05-02 2018-12-31 심포젠 에이/에스 인간화 ｐａｎ­ｈｅｒ 항체 조성물
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
CA2871882A1 (fr) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Methode de fabrication de conjugues d'anticorps a region fc comprenant au moins une entite de liaison qui se lie specifiquement a une cible et leurs utilisations
AU2013322710A1 (en) 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CN104768976B (zh) 2012-10-05 2020-09-22 阿菲博迪公司 Her3结合多肽
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
WO2014072305A1 (fr) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Protéines de liaison à l'antigène anti-her3/her4 se liant à la boucle en épingle à cheveux beta
AR093378A1 (es) 2012-11-08 2015-06-03 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
SG11201504293WA (en) 2012-12-03 2015-06-29 Merrimack Pharmaceuticals Inc Combination therapy for treating her2-positive cancers
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
KR20150127203A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
AU2014262566A1 (en) * 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
EP2821071A1 (fr) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Composés pour le traitement du cancer du sein
WO2015048008A2 (fr) 2013-09-24 2015-04-02 Medimmune, Llc Molécules de liaison spécifiques de her3 et utilisation desdites molécules
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
US10196455B2 (en) 2013-11-07 2019-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-HER3 antibody
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
IL295906A (en) 2014-03-21 2022-10-01 Abbvie Inc Antibodies against egfr and drug antibody conjugates
EP3125920B1 (fr) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol ou dibromodulcitol dans le traitement du carcinome non à petites cellules des poumons et du cancer des ovaires
MY195180A (en) 2014-04-10 2023-01-11 U3 Pharma Gmbh Anti-HER3 Antibody-Drug Conjugate
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
CN106459207B (zh) * 2014-05-14 2020-07-10 豪夫迈·罗氏有限公司 结合HER3β-发夹的抗HER3抗体
US20160045596A1 (en) 2014-08-05 2016-02-18 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
SG11201708491PA (en) * 2015-04-17 2017-11-29 Merrimack Pharmaceuticals Inc Combination treatments with seribantumab
EP3091033A1 (fr) 2015-05-06 2016-11-09 Gamamabs Pharma Anticorps anti-her3 humains et leurs utilisations
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP2018516263A (ja) 2015-05-29 2018-06-21 メリマック ファーマシューティカルズ インコーポレーティッド 癌併用療法
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
TWI724018B (zh) 2015-08-20 2021-04-11 英商益普生生物製藥有限公司 用於癌症治療之組合療法
EP3337478B1 (fr) 2015-08-21 2020-08-12 Ipsen Biopharm Ltd. Combinaison de médicaments renfermant de l'irinotécan liposomal, de l'oxaliplatin, du 5-fluorouracile et de la leucovorine pour le traitement du cancer pancréatique métastatique
WO2017035482A1 (fr) * 2015-08-27 2017-03-02 Merrimack Pharmaceuticals, Inc Polythérapies pour le traitement de cancers positifs à l'héréguline
EP3352859B1 (fr) 2015-09-24 2020-09-23 Expression Pathology, Inc. Quantification de la protéine met pour le traitement du cancer
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
EP3912998A3 (fr) 2015-10-23 2022-02-23 Merus N.V. Molécules de liaison qui inhibent la croissance d'un cancer
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
CN106854244B (zh) * 2015-12-09 2020-05-22 南京英瀚斯生物科技有限公司 一种针对her3的纳米抗体及其临床应用
US20180362654A1 (en) 2015-12-11 2018-12-20 Regeneron Pharmaceuticals, Inc. Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
KR20180119570A (ko) 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US20190153108A1 (en) 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
CA3027044A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-b7-h3 et conjugues anticorps-medicaments
CA3027033A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-cd98 et conjugues anticorps-medicament
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
JP2019521114A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
MX2019004783A (es) 2016-11-02 2019-08-12 Ipsen Biopharm Ltd Tratamiento de cancer gastrico usando terapias de combinacion que comprenden irinotecan liposomico oxaliplatino, 5-fluoruracilo (y leucovorina).
CN110049779A (zh) 2016-12-12 2019-07-23 第一三共株式会社 抗体-药物缀合物和免疫检查点抑制剂的组合
US20200157190A1 (en) 2016-12-19 2020-05-21 Abcam Plc Monovalent and divalent binding proteins
US11434289B2 (en) 2017-01-17 2022-09-06 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
CN117982673A (zh) 2017-02-28 2024-05-07 第一三共株式会社 抗her3抗体-药物偶联物的应用
JP2020511993A (ja) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
BR112019020507A2 (pt) 2017-03-31 2020-08-04 Merus N.V. agente de alvejamento de erbb-2 e um anticorpo bispecífico com locais de ligação de antígenos que ligam um epítopo em uma parte extracelular de erbb-2 e erbb-3 para tratamento de um indivíduo com um tumor positivo erbb-2, erbb-2 / erbb-3
WO2018195302A1 (fr) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anticorps anti-vtcn1 et conjugués anticorps-médicament
WO2018204153A1 (fr) * 2017-05-02 2018-11-08 Venomyx, Inc. Composition et procédés de traitement de l'envenimation par un serpent
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
WO2019031965A1 (fr) 2017-08-09 2019-02-14 Merus N.V. Anticorps qui se lient à l'egfr et à cmet
TW201919710A (zh) 2017-08-23 2019-06-01 日商第一三共股份有限公司 抗體－藥物結合物之製劑及其冷凍乾燥方法
JP7366745B2 (ja) 2017-08-31 2023-10-23 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
WO2019118318A1 (fr) 2017-12-12 2019-06-20 Calico Biolabs, Inc. Anticorps recombinant comprenant une chaîne lourde génétiquement fusionnée à une signature peptidique et ses utilisations
WO2019219889A1 (fr) 2018-05-18 2019-11-21 Glycotope Gmbh Anticorps anti-muc1
WO2020022363A1 (fr) 2018-07-25 2020-01-30 第一三共株式会社 Procédé efficace de fabrication d'un conjugué anticorps-médicament
JP7406488B2 (ja) 2018-07-27 2023-12-27 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
KR20210038625A (ko) 2018-07-31 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료
KR20210042120A (ko) 2018-08-06 2021-04-16 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 튜불린 저해제의 조합
TW202016317A (zh) 2018-08-23 2020-05-01 日商第一三共股份有限公司 抗體藥物結合物之感受性標記
CN112912109A (zh) 2018-09-20 2021-06-04 第一三共株式会社 通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
EP3909580A4 (fr) 2018-12-11 2022-09-07 Daiichi Sankyo Company, Limited Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de parp
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
WO2022078490A1 (fr) * 2020-10-15 2022-04-21 上海翰森生物医药科技有限公司 Anticorps anti-erbb3 ou fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
US20230414778A1 (en) 2020-11-11 2023-12-28 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024509914A (ja) 2021-03-11 2024-03-05 エレベーション オンコロジー， インコーポレイテッド ニューレグリン１（ｎｒｇ１）遺伝子融合に関連する腫瘍を処置するための抗ｅｒｂｂ３（ｈｅｒ３）モノクローナル抗体の投与量および投与
WO2023198138A1 (fr) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale
WO2023209591A1 (fr) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combinaison d'un conjugué anticorps-médicament avec un inhibiteur de l'ezh1 et/ou de l'ezh2
TW202400650A (zh) 2022-05-11 2024-01-01 日商第一三共股份有限公司 抗體與cd47抑制劑之組合
WO2024127366A1 (fr) 2022-12-16 2024-06-20 Pheon Therapeutics Ltd Anticorps dirigés contre la protéine 1 contenant le domaine cub (cdcp1) et leurs utilisations

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2149329C (fr) 1992-11-13 2008-07-15 Darrell R. Anderson Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6983227B1 (en) 1995-01-17 2006-01-03 Intertech Ventures, Ltd. Virtual models of complex systems
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
EP0896586B2 (fr) * 1996-03-27 2015-05-20 Genentech, Inc. ANTICORPS DE LA PROTEINE ErbB3
IL127891A0 (en) 1996-07-12 1999-10-28 Genentech Inc Chimeric heteromultimeter adhesins
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
GB2336695A (en) 1998-04-20 1999-10-27 Teamware Group Oy Modelling a work process
WO1999060023A1 (fr) 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
EP1792991A1 (fr) 1999-08-24 2007-06-06 Medarex, Inc. Anticorps humains contre CTLA-4 et leur utilisation
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2001078652A2 (fr) 2000-04-14 2001-10-25 Metabolon, Inc. Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique
KR20030007640A (ko) 2000-05-19 2003-01-23 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
CN101676400A (zh) 2000-07-31 2010-03-24 比洛克西治疗公司 在浮萍中表达生物活性多肽
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6871171B1 (en) 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP1228766A1 (fr) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
EP1283053A1 (fr) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de l'activité de HER3
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
JP4660094B2 (ja) 2002-03-26 2011-03-30 ゼンサン （シャンハイ） サイ−テク． リミテッド 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
WO2004000102A2 (fr) 2002-06-19 2003-12-31 Abgenix, Inc. Procede servant a predire une reponse a une therapie dirigee vers le recepteur du facteur de croissance epidermique
EP2366718A3 (fr) * 2002-06-28 2012-05-02 Domantis Limited Ligand
CA2521106A1 (fr) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Complexes intracellulaires utilises comme biomarqueurs
CA2534898A1 (fr) * 2003-08-08 2005-02-17 Immunomedics, Inc. Anticorps bispecifiques pour induire l'apoptose de cellules tumorales et malades
EP1664716A4 (fr) 2003-08-15 2008-08-13 Smithkline Beecham Corp Biomarqueurs contre le cancer
US8554486B2 (en) 2004-02-20 2013-10-08 The Mathworks, Inc. Method, computer program product, and apparatus for selective memory restoration of a simulation
JP4350148B2 (ja) 2004-03-31 2009-10-21 ザ ジェネラル ホスピタル コーポレイション 上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
EP2949764B1 (fr) 2004-05-27 2018-04-11 The Regents of The University of Colorado Procédés de prédiction du résultat clinique d'inhibiteurs du récepteur de facteur de croissance épidermique par les patients atteints du cancer
US7794960B2 (en) 2004-06-04 2010-09-14 Glaxosmithkline Llc Predictive biomarkers in cancer therapy
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
KR101235479B1 (ko) 2004-08-06 2013-02-20 제넨테크, 인크. 바이오마커를 사용한 분석 및 방법
AU2005272848A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20060136139A1 (en) 2004-10-12 2006-06-22 Elcock Adrian H Rapid computational identification of targets
WO2006044748A2 (fr) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. Predicteurs de reponse pour medicaments specifiques de la voie erbb
RU2007135216A (ru) 2005-02-23 2009-03-27 Мерримак Фармасьютикалз, Инк. (Us) Биспецифические связывающие агенты для модулирования биологической активности
WO2006096861A2 (fr) 2005-03-08 2006-09-14 Genentech, Inc. Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi)
US20090061422A1 (en) 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007015935A2 (fr) 2005-07-29 2007-02-08 Bayer Healthcare Llc Procedes diagnostiques permettant de predire le succes therapeutique, d'eviter les rechutes et d'obtenir une bonne survivance generale en therapie du cancer
WO2007041502A2 (fr) 2005-09-30 2007-04-12 Monogram Biosciences Procedes pour la determination de la sensibilite a la therapie cancereuse
CA2624613A1 (fr) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Methode pour predire ou surveiller la reponse d'un patient a un medicament de recepteur erbb
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2049568A2 (fr) 2006-04-07 2009-04-22 Københavns Universitet Fragments peptidiques dérivés du récepteur erbb
CA2650776A1 (fr) 2006-05-05 2007-11-15 Yale University Utilisation de profils de localisation subcellulaires comme indicateurs de pronostic ou indicateurs de prevision
WO2008008500A2 (fr) 2006-07-13 2008-01-17 Yale University Procédés pronostiques du cancer à partir de la localisation subcellulaire de biomarqueurs
WO2008073629A2 (fr) 2006-11-03 2008-06-19 Board Of Regents, The University Of Texas System Predicteurs bifonctionnels de sensibilite et de resistance a un traitement anti-cancereux
AU2007324868B2 (en) 2006-11-28 2014-03-20 Daiichi Sankyo Europe Gmbh Activated HER3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
BRPI0811156A2 (pt) 2007-05-11 2019-09-24 Enzon Pharmaceuticals Inc compostos antagonistas de rna para a modulação de her3
ES2433424T3 (es) 2008-08-15 2013-12-11 Merrimack Pharmaceuticals, Inc. Métodos y sistemas para predecir respuesta de células frente a un agente terapéutico
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
EA201200195A1 (ru) 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
WO2011139681A1 (fr) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Essais pour des anticorps anti-médicaments en présence d'homologues protéique endogènes abondants du médicament
WO2012006552A1 (fr) 2010-07-09 2012-01-12 Exelixis, Inc. Associations d'inhibiteurs de kinases destinées au traitement du cancer
RU2620071C2 (ru) * 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
CA2819554A1 (fr) 2010-12-10 2012-06-14 Merrimack Pharmaceuticals, Inc. Dosage et administration de conjugues scfv bispecifiques
US20140056898A1 (en) 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CA2828043A1 (fr) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Vaincre la resistance a des inhibiteurs de la voie erbb
TWI631136B (zh) 2011-04-19 2018-08-01 莫瑞麥克製藥公司 單特異性及雙特異性抗ｉｇｆ－１ｒ及抗ｅｒｂｂ３抗體
KR20140050609A (ko) 2011-05-06 2014-04-29 메리맥 파마슈티컬즈, 인크. 항-ＥｒｂＢ3 제제들을 포함하는 조합 요법들에서 독성의 약물-약물 상호작용들을 예방하는 방법들
WO2012177440A1 (fr) 2011-06-24 2012-12-27 Merrimack Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-erbb3 en association avec le paclitaxel
CA2839869A1 (fr) 2011-06-30 2013-01-03 Sanofi Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynecologiques
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies

Also Published As

Publication number Publication date
US9487588B2 (en) 2016-11-08
BRPI0808055A2 (pt) 2013-07-30
US20190292271A1 (en) 2019-09-26
CN101674846B (zh) 2014-07-02
US20110123523A1 (en) 2011-05-26
EP2716301B1 (fr) 2017-04-05
US8691225B2 (en) 2014-04-08
DK2129396T3 (da) 2013-11-25
JP5564266B2 (ja) 2014-07-30
US20090291085A1 (en) 2009-11-26
SI2129396T1 (sl) 2013-12-31
ZA200906360B (en) 2014-03-26
PL2716301T3 (pl) 2017-10-31
US7846440B2 (en) 2010-12-07
CY1114632T1 (el) 2016-10-05
EP3248617A2 (fr) 2017-11-29
WO2008100624A3 (fr) 2009-01-15
EP2716301A2 (fr) 2014-04-09
SG178789A1 (en) 2012-03-29
US20100266584A1 (en) 2010-10-21
HK1138771A1 (en) 2010-09-03
CA2678181C (fr) 2016-12-13
EP2716301A3 (fr) 2014-07-16
CR11029A (es) 2009-12-29
CO6231000A2 (es) 2010-12-20
KR20100014426A (ko) 2010-02-10
US20140234329A1 (en) 2014-08-21
AU2008216600B2 (en) 2013-09-05
HRP20170834T1 (hr) 2017-08-25
IL200373A0 (en) 2010-04-29
RS53042B (en) 2014-04-30
NZ579644A (en) 2012-05-25
SI2716301T1 (sl) 2017-07-31
US20170073427A1 (en) 2017-03-16
EP3248617A3 (fr) 2018-02-21
HRP20131113T1 (hr) 2014-01-17
HUE033472T2 (en) 2017-12-28
US8961966B2 (en) 2015-02-24
JP2010518820A (ja) 2010-06-03
PT2129396E (pt) 2013-11-18
ECSP099637A (es) 2009-12-28
MX2009008656A (es) 2009-11-10
EA020465B1 (ru) 2014-11-28
CN101674846A (zh) 2010-03-17
DK2716301T3 (en) 2017-07-31
US20220204642A1 (en) 2022-06-30
EP2129396A2 (fr) 2009-12-09
IL200373A (en) 2013-09-30
PL2129396T3 (pl) 2014-02-28
AU2008216600A1 (en) 2008-08-21
US20100056761A1 (en) 2010-03-04
ES2631727T3 (es) 2017-09-04
KR101598229B1 (ko) 2016-02-26
WO2008100624A2 (fr) 2008-08-21
ES2431940T3 (es) 2013-11-28
EP2647388A1 (fr) 2013-10-09
CA2678181A1 (fr) 2008-08-21
EA200901119A1 (ru) 2010-10-29
PT2716301T (pt) 2017-07-04
EP2129396B1 (fr) 2013-08-21
JP2014113167A (ja) 2014-06-26

Similar Documents

Publication Publication Date Title
MA31254B1 (fr) Anticorps contre erbb3 et leur utilisation
DK1966244T3 (da) Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130
MA33582B1 (fr) Anticorps contre l'ectodomaine de erbb3 et leurs utilisations
EA201400390A1 (ru) Антитела к tl1a и их применение
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA38498B1 (fr) Protéines de liaison anti-lag-3
TNSN06210A1 (fr) Nitro-oxydérivés de prostaglandines
TNSN07398A1 (fr) Anticorps contre la p-cadherine
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
EP2091563A4 (fr) Neutralisation d'anticorps monoclonaux contre le récepteur nogo-66 (ngr) et leurs utilisations
ATE553130T1 (de) Humanisierter anti-human-osteopontin-antikörper
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
TNSN08502A1 (en) High affinity antibodies to human il-6 receptor
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA31067B1 (fr) Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison.
NO20065252L (no) Behandling av forstyrrelser
TW200607815A (en) Anti-CD148 antibodies and binding epitopes therefor
MA33387B1 (fr) Polypeptides et procede de traitement
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde